Alembic Pharma Senior VP Rohit Garg Resigns

Alembic Pharmaceuticals Limited has disclosed the resignation of Mr. Rohit Garg from the position of Senior Vice President – Strategy & Business Excellence. The intimation was filed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Mr. Garg was relieved from his duties effective May 14, 2026, after the closure of business hours. The company confirmed that the necessary details regarding the change have been submitted to the stock exchanges as required by the regulations.

Resignation Details

The official communication to the exchanges outlined the specific circumstances surrounding the departure. The resignation marks the end of Mr. Garg's tenure with the pharmaceutical major.

Particulars	Details
Reason for change	Resignation
Date of cessation	14 May, 2026 (after closure of business hours)

Internal communications indicate that Mr. Garg submitted his resignation on March 17, 2026, citing personal reasons for his departure. He expressed gratitude for the support extended during his tenure of over five years and wished the organization well for the future.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-8.11%	-8.46%	-1.95%	-20.30%	-21.22%	-23.65%

Alembic Pharmaceuticals has secured a tentative approval from the United States Food and Drug Administration (USFDA) for its 300 MG Darolutamide Tablets. The approved product is a generic equivalent to the reference listed drug, Nubeqa Tablets, which is an established branded formulation in the oncology segment.

Regulatory Approval Details

The tentative approval from the USFDA represents a key regulatory development for Alembic Pharmaceuticals as it advances its generic pharmaceutical portfolio in the United States. The following table summarizes the key details of this approval:

Parameter:	Details
Approval Type:	Tentative Approval
Regulatory Authority:	USFDA
Product:	Darolutamide Tablets
Strength:	300 MG
Reference Listed Drug:	Nubeqa Tablets
Estimated US Market Size:	$3.155 Billion

US Market Opportunity

The US market for Darolutamide Tablets is estimated at $3.155 billion, underscoring the commercial significance of this regulatory clearance for Alembic Pharmaceuticals. A tentative approval indicates that the USFDA has reviewed and found the application to be approvable, pending the resolution of any existing patent or exclusivity protections associated with the reference listed drug before a final approval can be granted.

Key Highlights

Product: 300 MG Darolutamide Tablets
Equivalent To: Nubeqa Tablets (reference listed drug)
Approval Status: Tentative Approval from USFDA
Estimated US Market Size: $3.155 billion

This tentative approval adds to Alembic Pharmaceuticals' pipeline of generic products targeting the US market, with the company positioned to potentially commercialize the product upon receipt of final approval in accordance with applicable regulatory and patent timelines.